A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers

The combination of weekly topotecan and docetaxel has clinical benefit and is well tolerated in this heavily treated patient population. Patients with platinum-resistant tumors had clinical benefit and should be considered for further study with this regimen.